Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells

Oncotarget

Volumn 8, Issue 34, 2017, Pages 56968-56979

  Van Audenaerde, Jonas R M ^a   Dev Waele, Jorrit ^a   Marcq, Elly ^a   Van Loenhout, Jinthe ^a   Lion, Eva ^a   Van den Bergh, Johan M J ^a   Jesenofsky, Ralf ^b   Masamune, Atsushi ^c   Roeyen, Geert ^d   Pauwels, Patrick ^a,d   Lardon, Filip ^a   Peeters, Marc ^a,d   Smits, Evelien L J ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Immunotherapy; Interleukin 15 (IL 15); Natural killer (NK) cells; Pancreatic cancer (PDAC); Pancreatic stellate cells (PSC)

Indexed keywords

ECALECTIN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN 15; LIGAND; MICA B PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; ULBP PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL INTERACTION; CELL STIMULATION; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PANCREAS CANCER; PANCREATIC CELL LINE; PANCREATIC STELLATE CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 85029078024     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.18185     Document Type: Article

References (66)

1. Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J, Huang K. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016; 2016:8962321. doi: 10.1155/2016/8962321
2. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015; 15:8-18. doi: 10.1016/j.pan.2014.10.001
3. Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015; 9:3529-45. doi: 10.2147/ DDDT.S60328
4. Sclafani F, Iyer R, Cunningham D, Starling N. Management of metastatic pancreatic cancer: current treatment options and potential new therapeutic targets. Crit Rev Oncol Hematol. 2015; 95:318-36. doi: 10.1016/j. critrevonc.2015.03.008
5. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014; 371:1039-49. doi:10.1056/NEJMra1404198
6. Aroldi F, Bertocchi P, Savelli G, Rosso E, Zaniboni A. Pancreatic cancer: new hopes after first line treatment. World J Gastrointest Oncol. 2016; 8:682-7. doi: 10.4251/ wjgo.v8.i9.682
7. Jimenez-Luna C, Prados J, Ortiz R, Melguizo C, Torres C, Caba O. Current status of immunotherapy treatments for pancreatic cancer. J Clin Gastroenterol. 2016; 50:836-48. doi: 10.1097/MCG.0000000000000623
8. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817-25. doi: 10.1056/NEJMoa1011923
9. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015; 107:pii: dju413. doi: 10.1093/jnci/ dju413
10. Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol. 2015; 21:9297-316. doi: 10.3748/wjg.v21.i31.9297
11. Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014; 40:118-28 doi: 10.1016/j.ctrv.2013.04.004
12. Watt J, Kocher HM. The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. Oncoimmunology. 2013; 2:e26788. doi: 10.4161/ onci.26788
13. Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Front Physiol. 2014; 5:52. doi: 10.3389/ fphys.2014.00052
14. Lunardi S, Muschel RJ, Brunner TB. The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett. 2014; 343:147-55. doi:10.1016/j.canlet.2013.09.039
15. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccinebased immunotherapy. Hum Vaccin Immunother. 2014; 10:3354-68. doi: 10.4161/hv.34392
16. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012; 18:4266-76. doi: 10.1158/1078-0432. CCR-11-3114
17. Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. Eur J Cancer. 2014; 50:2570-82. doi: 10.1016/j.ejca.2014.06.021
18. Hurwitz AA, Lee S, Knox S, Kohrt H, Verdeil G, Romano E, Margolin K, Urba WJ, Speiser DE. 29th Annual meeting of the Society for Immunotherapy of Cancer (SITC). J Immunother Cancer. 2015; 3:17. doi: 10.1186/ s40425-015-0062-4
19. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373:1627-39. doi: 10.1056/ NEJMoa1507643
20. Riley JL. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med. 2013; 369:187-9. doi: 10.1056/NEJMe1305484
21. Mei L, Du W, Ma WW. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016; 7:487-94. doi:10.21037/jgo.2016.03.03
22. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012; 33:35-41. doi: 10.1016/j.tips.2011.09.004
23. Goldberg JL, Sondel PM. Enhancing cancer immunotherapy via activation of innate immunity. Semin Oncol. 2015; 42:562-72. doi: 10.1053/j.seminoncol.2015.05.012
24. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994; 84:2221-8
25. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016; 17:1025-36. doi: 10.1038/ni.3518
26. Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother. 2012; 35:629-40. doi: 10.1097/ CJI.0b013e31826c8a4f
27. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol. 2011; 28:466-74. doi: 10.1007/s12032-010-9480-9
28. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013; 170:365-72. doi:10.1016/j.jconrel.2013.05.041
29. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691-703. doi: 10.1056/ NEJMoa1304369
30. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25:719-34. doi: 10.1016/j.ccr.2014.04.005
31. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25:735-47. doi: 10.1016/j.ccr.2014.04.021
32. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110:20212-7. doi: 10.1073/pnas.1320318110
33. Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med. 2016; 4:165. doi: 10.21037/atm.2016.05.11
34. Varadhachary GR, Wolff RA. Current and evolving therapies for metastatic pancreatic cancer: are we stuck with cytotoxic chemotherapy? J Oncol Pract. 2016; 12:797-805. doi: 10.1200/JOP.2016.015586
35. Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M, Rosenberg SA, Royal RE. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer Immunol Immunother. 2010; 59:1757-69. doi: 10.1007/ s00262-010-0897-y
36. Mao Y, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, Masvidal L, Liang S, Murray S, Larsson O, Kiessling R, Lundqvist A. IL-15 activates mTOR and primes stressactivated gene expression leading to prolonged antitumor capacity of NK cells. Blood. 2016; 128:1475-89. doi:10.1182/blood-2016-02-698027
37. Rautela J, Huntington ND. IL-15 signaling in NK cell cancer immunotherapy. Curr Opin Immunol. 2016; 44:1-6. doi: 10.1016/j.coi.2016.10.004
38. Patidar M, Yadav N, Dalai SK. Interleukin 15: a key cytokine for immunotherapy. Cytokine Growth Factor Rev. 2016; 31:49-59. doi: 10.1016/j.cytogfr.2016.06.001
39. Yoshida Y, Tasaki K, Miyauchi M, Narita M, Takenaga K, Yamamoto H, Yaaguchi T, Saisho H, Sakiyama S, Tagawa M. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene. Cancer Gene Ther. 2000; 7:324-31. doi: 10.1038/sj.cgt.7700118
40. Jing W, Chen Y, Lu L, Hu X, Shao C, Zhang Y, Zhou X, Zhou Y, Wu L, Liu R, Fan K, Jin G. Human umbilical cord blood-derived mesenchymal stem cells producing IL15 eradicate established pancreatic tumor in syngeneic mice. Mol Cancer Ther. 2014; 13:2127-37. doi: 10.1158/1535-7163.MCT-14-0175
41. Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer. 2011; 11:194. doi:10.1186/1471-2407-11-194
42. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-inhuman clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015; 33:74-82. doi:10.1200/JCO.2014.57.3329
43. Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016; 5:e1163462. doi:10.1080/2162402X.2016.1163462
44. Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW. IL-15 superagonist/ IL-15RalphaSushi-Fc fusion complex (IL-15SA/ IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget. 2016; 7:16130-45. doi:10.18632/oncotarget.7470
45. Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, et al. The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res. 2016; 22:596-608. doi: 10.1158/1078-0432. CCR-15-1419
46. Aparicio-Pages MN, Verspaget HW, Pena AS, Lamers CB. Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract. J Clin Lab Immunol. 1991; 35:27-32
47. Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, Jiang KR, Wu JL, Gao WT, Li Q, Du Q, Miao Y. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med. 2013; 11:262. doi: 10.1186/1479-5876-11-262
48. Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol. 2007; 8:1345-52. doi: 10.1038/ni1524
49. Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012; 119:3734-43. doi: 10.1182/blood-2011-11-392951
50. Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol. 2013; 4:449. doi: 10.3389/fimmu.2013.00449
51. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, Niki T, Hirashima M, Blazar BR, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012; 119:3064-72. doi: 10.1182/ blood-2011-06-360321
52. da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014; 2:410-22. doi:10.1158/2326-6066.CIR-13-0171
53. Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X, Zhang Y. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015; 29:635-41. doi: 10.1016/j.intimp.2015.09.017
54. Feng S, Madsen SH, Viller NN, Neutzsky-Wulff AV, Geisler C, Karlsson L, Soderstrom K. Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro. Immunology. 2015; 145:367-79. doi:10.1111/imm.12449
55. Hromadnikova I, Pirkova P, Sedlackova L. Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors. Mediators Inflamm. 2013; 2013:405295. doi: 10.1155/2013/405295
56. Sun H, Sun C, Xiao W. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine. 2014; 65:33-41 doi: 10.1016/j.cyto.2013.09.016
57. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D, Wesch D. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand J Immunol. 2007; 66:320-8. doi: 10.1111/j.1365-3083.2007.01963.x
58. Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2016 Oct 21. doi: 10.1136/gutjnl-2016-311585. [Epub ahead of print]
59. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13:2151-7. doi: 10.1158/1078-0432.CCR-06-2746
60. Jesnowski R, Furst D, Ringel J, Chen Y, Schrodel A, Kleeff J, Kolb A, Schareck WD, Lohr M. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab Invest. 2005; 85:1276-91. doi:10.1038/labinvest.3700329
61. Hamada S, Masamune A, Yoshida N, Takikawa T, Shimosegawa T. IL-6/STAT3 plays a regulatory role in the interaction between pancreatic stellate cells and cancer cells. Dig Dis Sci. 2016; 61:1561-71. doi: 10.1007/ s10620-015-4001-5
62. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grunert A, Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998; 115:421-32
63. Moir JA, Mann J, White SA. The role of pancreatic stellate cells in pancreatic cancer. Surg Oncol. 2015; 24:232-8. doi:10.1016/j.suronc.2015.05.002
64. Lion E, Anguille S, Berneman ZN, Smits EL, Van Tendeloo VF. Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One. 2011; 6:e20952. doi: 10.1371/journal.pone.0020952
65. Van den Bergh JM, Guerti K, Willemen Y, Lion E, Cools N, Goossens H, Vorsters A, Van Tendeloo VF, Anguille S, Van Damme P, Smits EL. HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med. 2014; 18:1372-80. doi: 10.1111/jcmm.12284
66. Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, Van Tendeloo VF, de Vries IJ, Adema GJ, et al. Engineering monocyte-derived dendritic cells to secrete interferon-alpha enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol Immunother. 2015; 64:831-42. doi: 10.1007/s00262-015-1688-2